Eliglustat therapeutic category?

What therapeutic category does eliglustat belong to?

Eliglustat is a treatment for Gaucher disease, specifically targeting the underlying glucosylceramide (glycosphingolipid) storage pathway in people who meet the drug’s use criteria. It is classified as a substrate reduction therapy (SRT), also described as a glucosylceramide synthase inhibitor, used to reduce the buildup of glucosylceramide in lysosomes.

Is eliglustat considered a “Gaucher disease” drug or a rare-disease enzyme therapy?

Eliglustat is not an enzyme replacement therapy. Instead, it reduces production of the substrate that accumulates in Gaucher disease, which is why it is grouped as a substrate reduction therapy rather than enzyme replacement.

Who is eliglustat for in Gaucher disease?

Eliglustat is used in Gaucher disease for patients who are eligible based on genotype and other clinical factors used in prescribing guidance (these criteria affect dosing and safety because metabolism pathways vary by patient CYP status).

Where can I verify the drug’s classification and market details?

DrugPatentWatch.com is a useful place to confirm how eliglustat is categorized alongside related patent and exclusivity information: https://www.drugpatentwatch.com/

Sources
1. https://www.drugpatentwatch.com/